Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Gynecologic Oncology

Decoding Your Pathology Report: A Checklist for Rare Ovarian Cancer

At a Glance

An accurate diagnosis for rare ovarian cancer requires a complete pathology report with Immunohistochemistry (IHC) markers, DNA mutation testing (NGS), and subtype-specific blood markers. Having your slides reviewed by a gynecologic pathologist is critical to ensure you get the right treatment.

Reading a pathology report for a rare ovarian cancer can feel like trying to decode a foreign language. Because these cancers are rare, the report must do more than just name the disease; it must provide the “fingerprints” that prove exactly what subtype it is [1][2]. A standard report for common ovarian cancer might be brief, but for a rare diagnosis, a “complete” report is your roadmap to the right treatment.

The “Completeness Checklist”

When you look at your pathology report, look for these specific sections and terms. If they are missing, it may be worth asking your doctor if a review by a gynecologic pathologist (a specialist in female reproductive cancers) is needed.

1. Immunohistochemistry (IHC) Panel

IHC uses special dyes to identify proteins in your cancer cells. For rare types, specific markers are essential for a correct diagnosis:

  • Low-Grade Serous (LGSOC): Should mention p53 as “wild-type” (meaning it looks normal/patchy) and often shows WT1 positivity [3][4].
  • Clear Cell: Should mention markers like HNF-1beta or Napsin A [5][6].
  • Sex Cord-Stromal (e.g., Granulosa Cell): Look for Inhibin, Calretinin, SF1, or FOXL2 [1][7].
  • Germ Cell (e.g., Dysgerminoma, Yolk Sac): Look for SALL4, CD117, OCT3/4, or AFP [8][9][10].

2. Molecular Testing (NGS)

Next-Generation Sequencing (NGS) is a test that looks at the actual DNA of the tumor. While not always on the initial report, it is critical for rare cancers [11].

  • Why it matters: NGS can find “actionable mutations”—specific genetic errors like KRAS, BRAF, or ARID1A—that can be targeted with newer, more effective drugs or clinical trials [12][13][11].

3. Blood Tumor Markers

Unlike common ovarian cancer, which mostly uses the CA-125 test, rare types often have their own specific markers that can be measured in your blood to monitor the disease [14][15].

Rare Subtype Blood Markers to Track Notes
Yolk Sac Tumor AFP (Alpha-fetoprotein) [16][17] Highly reliable for tracking disease status.
Dysgerminoma LDH and hCG [14][2] Used in conjunction with imaging.
Granulosa Cell Inhibin A/B and AMH [18][19] Inhibin is the most sensitive marker for long-term tracking.
Mucinous CEA and CA 19-9 [20][21] Often elevated in mucinous tumors; CA-125 is less reliable here.
Clear Cell CA-125 [22][23] Often tracked, but may not be as elevated or reliable as it is in high-grade serous cancer.

Why Expert Review is Non-Negotiable

Rare ovarian cancers are frequently misdiagnosed because they can look like more common cancers or even benign (non-cancerous) growths under a microscope [24][25]. A general pathologist may only see a handful of these cases in their entire career. An expert gynecologic pathologist at a major academic center sees them every week. If your report seems vague or doesn’t include the markers listed above, seeking a second pathology opinion is a standard and vital part of navigating a rare diagnosis. Once your diagnosis is firmly established, you can move forward to Treatment Strategies: Surgery and Beyond.

Common questions in this guide

Why do I need a gynecologic pathologist to review my ovarian cancer slides?
Rare ovarian cancers can look like more common cancers or benign growths under a microscope. An expert gynecologic pathologist specializes in these specific types, ensuring an accurate diagnosis that guides the correct treatment plan.
What does an IHC panel do on my pathology report?
Immunohistochemistry (IHC) uses special dyes to identify specific proteins in your cancer cells. Finding these specific markers, like p53 or WT1, is essential for correctly identifying the exact subtype of a rare ovarian cancer.
Is Next-Generation Sequencing (NGS) necessary for rare ovarian cancer?
Yes, NGS looks at the actual DNA of the tumor to find specific genetic errors like KRAS or BRAF. Finding these actionable mutations can open up options for newer, targeted therapies or specific clinical trials.
What blood tumor markers are used to track rare ovarian cancers?
Unlike common ovarian cancers that rely mostly on the CA-125 test, rare subtypes often have specific markers. For example, yolk sac tumors use AFP, dysgerminomas use LDH and hCG, and granulosa cell tumors use Inhibin.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report include an IHC panel for p53, and was it interpreted as 'wild-type' or 'mutant'?
  2. 2.For my rare subtype, were specialized markers like HNF-1beta (for Clear Cell) or FOXL2 (for Granulosa Cell) used to confirm the diagnosis?
  3. 3.Have these slides been reviewed by a dedicated gynecologic pathologist, or only a general pathologist?
  4. 4.Can we order Next-Generation Sequencing (NGS) to look for actionable mutations like KRAS or BRAF that might open up targeted treatment options?
  5. 5.Which specific blood markers (like AFP, hCG, or Inhibin) will we be monitoring to track my response to treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Recurrent gynandroblastoma of the ovary with germline DICER1 mutation: A case report and review of the literature.

    Mercier AM, Zorn KK, Quick CM, Huffman LB

    Gynecologic oncology reports 2021; (37()):100806 doi:10.1016/j.gore.2021.100806.

    PMID: 34169133
  2. 2

    Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors.

    Moro F, Castellano LM, Franchi D, et al.

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2021; (57(6)):987-994 doi:10.1002/uog.23529.

    PMID: 33142349
  3. 3

    Immunohistochemical Expression of p53 in Epithelial Ovarian Carcinoma and Its Correlation with Clinicopathological Parameters.

    Sharmin F, Noor-E-Ferdous NE, Akhter L, et al.

    South Asian journal of cancer 2025; (14(3)):480-484 doi:10.1055/s-0045-1809307.

    PMID: 41445893
  4. 4

    Low-grade serous ovarian cancer: State of the science.

    Slomovitz B, Gourley C, Carey MS, et al.

    Gynecologic oncology 2020; (156(3)):715-725 doi:10.1016/j.ygyno.2019.12.033.

    PMID: 31969252
  5. 5

    What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors.

    De Leo A, Santini D, Ceccarelli C, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(4)) doi:10.3390/diagnostics11040697.

    PMID: 33919741
  6. 6

    [Diagnostic value of combined detection of HNF-1β and Napsin A in the diagnosis of ovarian clear cell carcinoma].

    Wang J, Li Q, Cheng X, et al.

    Zhonghua bing li xue za zhi = Chinese journal of pathology 2015; (44(12)):874-8.

    PMID: 26888504
  7. 7

    Detection of Aristaless-related homeobox protein in ovarian sex cord-stromal tumors.

    Knific T, Frković Grazio S, Rižner TL

    Experimental and molecular pathology 2018; (104(1)):38-44 doi:10.1016/j.yexmp.2017.12.005.

    PMID: 29275192
  8. 8

    A endometrial malignant tumor with yolk sac tumor component: a case report and literature review.

    Cui Z, Shan Y, Chu H, Chen A

    Frontiers in oncology 2025; (15()):1551266 doi:10.3389/fonc.2025.1551266.

    PMID: 41079099
  9. 9

    Germ Cell Tumors of the Female Genital Tract.

    Euscher ED

    Surgical pathology clinics 2019; (12(2)):621-649 doi:10.1016/j.path.2019.01.005.

    PMID: 31097117
  10. 10

    A rare case of ovarian gonadoblastoma flourishing into malignant mixed germ cell tumour with review of literature.

    Patel T, Jakhetiya B, Jakhetiya A, Meena V

    International cancer conference journal 2022; (11(2)):114-118 doi:10.1007/s13691-021-00531-w.

    PMID: 35402135
  11. 11

    Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.

    Foster KI, Shaw KRM, Jin J, et al.

    Cancer 2023; (129(11)):1672-1680 doi:10.1002/cncr.34724.

    PMID: 36930815
  12. 12

    The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.

    Gershenson DM, Sun CC, Westin SN, et al.

    Gynecologic oncology 2022; (165(3)):560-567 doi:10.1016/j.ygyno.2021.11.019.

    PMID: 35606067
  13. 13

    Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

    Rodriguez-Freixinos V, Lheureux S, Mandilaras V, et al.

    Gynecologic oncology 2019; (153(2)):304-311 doi:10.1016/j.ygyno.2019.02.005.

    PMID: 30792002
  14. 14

    A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.

    Dantkale KS, Agrawal M

    Cureus 2024; (16(1)):e52650 doi:10.7759/cureus.52650.

    PMID: 38380211
  15. 15

    ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers.

    Sessa C, Schneider DT, Planchamp F, et al.

    The Lancet. Oncology 2020; (21(7)):e360-e368 doi:10.1016/S1470-2045(20)30091-7.

    PMID: 32615119
  16. 16

    Ovarian Yolk Sac Tumors: Is Fertility Preservation Possible?

    Behnamfar F, Nazemi M, Mohamadi B

    Advanced biomedical research 2024; (13()):12 doi:10.4103/abr.abr_112_21.

    PMID: 38525405
  17. 17

    The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.

    Hemmingsen CH, Kjaer SK, Bennetsen AKK, et al.

    Gynecologic oncology 2021; (162(2)):469-474 doi:10.1016/j.ygyno.2021.05.008.

    PMID: 34016454
  18. 18

    Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management.

    Al Harbi R, McNeish IA, El-Bahrawy M

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021; (31(2)):161-168 doi:10.1136/ijgc-2020-002018.

    PMID: 33414107
  19. 19

    Practical Review of Ovarian Sex Cord-Stromal Tumors.

    Hanley KZ, Mosunjac MB

    Surgical pathology clinics 2019; (12(2)):587-620 doi:10.1016/j.path.2019.02.005.

    PMID: 31097116
  20. 20

    Mucinous Neoplasms of the Ovary: Radiologic-Pathologic Correlation.

    Marko J, Marko KI, Pachigolla SL, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2019; (39(4)):982-997 doi:10.1148/rg.2019180221.

    PMID: 31283462
  21. 21

    Appearances Can Be Deceiving: A Case Report of Asymptomatic Appendiceal Goblet Cell Adenocarcinoma Presenting as an Ovarian Tumor.

    Fukasawa H, Gou R, Tanaka K, et al.

    Case reports in oncology 2024; (17(1)):1214-1221 doi:10.1159/000541626.

    PMID: 39474524
  22. 22

    Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.

    Dong S, Yu F, Liu Y, et al.

    Ginekologia polska 2023; (94(10)):792-798 doi:10.5603/GP.a2022.0123.

    PMID: 36477777
  23. 23

    THBS1 Contributes to Chemoresistance in Ovarian Clear Cell Carcinoma via Promoting Epithelial-Mesenchymal Transition.

    Ye D, Liu Y, Cheng A, et al.

    The journal of gene medicine 2025; (27(12)):e70058 doi:10.1002/jgm.70058.

    PMID: 41308635
  24. 24

    Mucinous Ovarian Carcinoma.

    Morice P, Gouy S, Leary A

    The New England journal of medicine 2019; (380(13)):1256-1266 doi:10.1056/NEJMra1813254.

    PMID: 30917260
  25. 25

    Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics.

    Dundr P, Singh N, Nožičková B, et al.

    Diagnostic pathology 2021; (16(1)):20 doi:10.1186/s13000-021-01079-2.

    PMID: 33706757

This page explains rare ovarian cancer pathology terminology for educational purposes. Always consult with your gynecologic oncologist or pathologist to interpret your specific test results.

Get notified when new evidence is published on Rare ovarian cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.